Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Bioorg Med Chem Lett
; 18(24): 6486-9, 2008 Dec 15.
Article
em En
| MEDLINE
| ID: mdl-18986805
ABSTRACT
The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was profiled in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Pirimidinas
/
Proteínas Inibidoras de Quinase Dependente de Ciclina
/
Imidazóis
Limite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Bioorg Med Chem Lett
Assunto da revista:
BIOQUIMICA
/
QUIMICA
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Reino Unido